Delpharm
- Company typePrivate
- Founded1988
- HeadquartersIssy-les-moulineaux, France
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Delpharm firmographics
Firmographics- Name
- Delpharm
- Legal name
- DELPHARM INDUSTRIE
- Website
- http://www.delpharm.com/
- Company type
- Private
- Founded year
- 1988
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Ownership category
- akta.pro rank
Delpharm industry classification
Industry- Product category
- Pharmaceutical Contract Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
- akta.pro secondary industry
- Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Delpharm is headquartered
LocationHeadquarters
- HQ city
- Issy-les-moulineaux
- HQ country
- France
- HQ region
- Europe
Offices9 records
Markets served
Delpharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Others
Revenue model
- CDMO Pharmaceutical Manufacturing Services: Delpharm generates revenue through contract development and manufacturing services for the pharmaceutical industry. As a CDMO, the company develops and manufactures medicines on behalf of pharmaceutical laboratories. Revenue is generated through long-term partnerships with pharmaceutical companies for drug product manufacturing across multiple dosage forms. The company reports approximately €1.1 billion in annual revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Delpharm product offering
Product offeringCore offering
Delpharm is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical drug development and manufacturing services for pharmaceutical laboratories. The company develops and produces medicines on behalf of clients across four major dosage form categories: solid oral, semi-solid, non-sterile liquid, and sterile (including pre-filled syringes). It operates 18 production sites and 3 development centers across Europe and North America, with integrated pharmaceutical development, regulatory affairs, and visual inspection/secondary packaging capabilities.
Product overview
Delpharm is a leading Contract Development and Manufacturing Organization (CDMO) providing comprehensive pharmaceutical manufacturing services. The company operates a multi-site network across Europe and North America with 18 production sites and 3 development centers, generating €1.1 billion in revenue. Delpharm's core offering spans four main pharmaceutical dosage form categories: solid oral forms (tablets, capsules, sachets), semi-solid forms (creams, ointments, suppositories), non-sterile liquids (solutions, syrups, nasal sprays), and sterile forms (pre-filled syringes, injectable solutions). The company also provides integrated pharmaceutical development services and regulatory affairs support. With a capacity exceeding 300 million liquid units annually and over 8,000 product references, Delpharm serves 170 clients across 140 countries, positioning itself among the top 5 internationalCDMOs.
Differentiator
Problem solved
Functional benefit
Brands
- Delpharm Academy: Internal training and development program for Delpharm employees offering in-person and online training courses, with over 170 training sessions organized and 1,500+ employees trained in 2023.
Products and services
- Solid Oral Dosage Forms Manufacturing
Quantifiable outcome
- Over 300 million liquid pharmaceutical units produced per year
- +5 more outcomes
Companies that use Delpharm
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
Delpharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Delpharm partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- ACVmed Consortium (Université Bourgogne Europe, École de Biologie Industrielle)coreDelpharm Dijon participates in the ACVmed project alongside Université Bourgogne Europe and École de Biologie Industrielle. The project aims to measure and reduce the carbon footprint of pharmaceutical manufacturing processes through a life cycle assessment (LCA) approach. This pilot project, supported by Santenov Dijon Bourgogne and Dijon Métropole, develops analytical methods applied to a concrete industrial case and strengthens teams' competencies in decarbonation. This initiative is part of Delpharm's commitment to the environmental transition of its industrial activities.
- Santenov Dijon BourgogneminorSupporting partner in the ACVmed decarbonation project at Delpharm Dijon, alongside Dijon Métropole.
- Dijon MétropoleminorSupporting partner in the ACVmed decarbonation project at Delpharm Dijon.
Scale indicators14 records
Recent moves6 records
Expansion highlights5 records
Delpharm competitors and assessment
Company assessmentDirect peers
- Recipharm: Swedish-headquartered CDMO with comparable scale (around €1.2B revenue at acquisition) and similar multi-form capabilities across solid, semi-solid, sterile, and biologics. Acquired by EQT in 2021, making it a near-direct comparable for a private CDMO of Delpharm's scale and geography.
- Fareva: French privately-held CDMO with comparable European footprint and multi-form pharmaceutical manufacturing capabilities. As a France-headquartered private competitor with similar customer profile (pharma laboratories), Fareva is one of Delpharm's closest direct competitors in Europe.
- Siegfried Holding: Swiss-listed CDMO (SIX: SFZN) with similar revenue scale (CHF ~1.3B) and capabilities across small-molecule API and drug product manufacturing. A closely comparable publicly-traded peer with comparable dosage form breadth and European footprint.
- Aenova Group: German privately-held CDMO owned by BC Partners with comparable scale (reportedly ~€800M+ revenue) and similar multi-form capabilities including solids, semi-solids, liquids, and sterile. Direct European CDMO competitor.
- Vetter Pharma: German privately-held CDMO specializing in aseptic fill-finish of prefilled syringes, cartridges, and vials. Direct comparable for Delpharm's sterile manufacturing business at Tours, particularly for complex biologics and injectable therapeutics.
- Almac Group: Northern Ireland privately-held CDMO with comparable capabilities in pharmaceutical development, commercial manufacturing, and clinical supply across solid dose and sterile forms. Direct competitor for European pharma development and manufacturing contracts.
- Famar Health Care Services: Greek-headquartered European CDMO with comparable manufacturing services across multiple dosage forms including sterile, semi-solid, and liquid pharmaceutical forms. Direct European competitor for contract manufacturing services.
Broad incumbents
- Catalent (Novo Holdings): U.S.-based large-scale CDMO with much broader biologics and gene therapy capabilities, recently acquired by Novo Holdings for ~$16.5B. Comparable in drug product services but operates at significantly larger scale with deeper biologics exposure than Delpharm.
- Lonza Group: Swiss-listed global CDMO leader (SIX: LONN) with ~CHF 6B+ revenue and leadership position in biologics manufacturing, cell and gene therapy, and small molecules. Overlaps with Delpharm in sterile fill-finish and solid dose but at materially larger scale and biologics depth.
- Thermo Fisher Scientific (Pharma Services): U.S.-listed life sciences giant (NYSE: TMO) with a substantial Pharma Services CDMO segment (formerly Patheon) that competes broadly across the full CDMO value chain. Operates at much larger scale with deeper resources than Delpharm across both small molecule and biologics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks2 records
Key highlights7 records
Customer concentration
Delpharm social profiles
Digital presenceDelpharm compliance and trust
Trust signalCompliance12 records
Delpharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Delpharm leadership team
Management profileNumber of profiles
Profiles12 records
Delpharm subsidiaries and ownership
Company hierarchySubsidiaries8 records
Delpharm funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Delpharm M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Delpharm
What does Delpharm do?
Delpharm is a Contract Development and Manufacturing Organization (CDMO) providing pharmaceutical drug development and manufacturing services for pharmaceutical laboratories. The company develops and produces medicines on behalf of clients across four major dosage form categories: solid oral, semi-solid, non-sterile liquid, and sterile (including pre-filled syringes). It operates 18 production sites and 3 development centers across Europe and North America, with integrated pharmaceutical development, regulatory affairs, and visual inspection/secondary packaging capabilities.
Is Delpharm a public or private company?
Delpharm is a private company. It is classified as unknown and is currently operating.
When was Delpharm founded?
Delpharm was founded in 1988. It employs 5,001 to 10,000 people.
Where is Delpharm based?
Delpharm is headquartered in Issy-les-moulineaux, France, in the Europe region.
How does Delpharm make money?
One revenue line is on record: CDMO Pharmaceutical Manufacturing Services.
Who are Delpharm's main competitors?
Direct peers on record are Recipharm, Fareva, Siegfried Holding, Aenova Group, Vetter Pharma, Almac Group and Famar Health Care Services. Broad incumbents are Catalent (Novo Holdings), Lonza Group and Thermo Fisher Scientific (Pharma Services).
Does Delpharm have an API?
No public API is recorded for Delpharm.
What industry is Delpharm in?
Delpharm's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO. Its NAICS code is 325412 and its SIC code is 2834.